Plain-English translation of NCT05169112 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After prostate cancer surgery, about 40% of men experience cancer recurrence—meaning cancer cells return and grow again. This trial is testing whether adding one year of hormonal therapy called immediately after surgery can prevent that recurrence in men at high risk. The medication works by blocking male hormones that can fuel prostate cancer growth.
Currently, doctors don't routinely give hormonal therapy right after prostate surgery, even though men at high risk of recurrence often face poor outcomes if cancer does return. This study aims to find out whether starting this medication early—before any signs of recurrence—can protect men from this outcome and improve their long-term survival.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either standard care alone or standard care plus the study medication. If assigned to receive the medication, you would receive four injections over one year—one injection every three months into your muscle. You would likely have follow-up visits to monitor your PSA levels and check for any side effects from the treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Canada